Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262121 | 0.89 | GAA (0.41) | PTGS2MAPTGAACYP2C9CYP1A2 | |
| SCHEMBL9751895 | 0.89 | GAA (0.41) | PTGS2MAPTGAACYP2C9CYP1A2 | |
| SCHEMBL29906122 | 0.89 | GAA (0.41) | PTGS2MAPTGAACYP2C9CYP1A2 | |
| SCHEMBL2035330 | 0.87 | PTGS2 (0.39) | PTGS2MAPTGAACYP3A4CYP2C9 | |
| SCHEMBL263717 | 0.87 | PTGS2 (0.39) | PTGS2MAPTGAACYP2C9CYP1A2 | |
| SCHEMBL8416013 | 0.86 | BCHE (0.44) | MAPTGAACYP2C9CYP1A2MAPK1 | |
| SCHEMBL28861875 | 0.85 | RARB (0.43) | MAPTALDH1A1 | |
| SCHEMBL262956 | 0.85 | GAA (0.43) | PTGS2MAPTGAACYP2C9CYP1A2 | |
| SCHEMBL7912542 | 0.85 | GAA (0.43) | PTGS2MAPTGAACYP2C9CYP1A2 | |
| SCHEMBL10894240 | 0.85 | HRH3 (0.39) | PTGS2MAPTGAACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431039-B2 | Mesogenic stabilizers | TRANSITIONS OPTICAL, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2013022607-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20120002141-A1 | MESOGENIC STABILIZERS | TRANSITIONS OPTICAL, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120002141-A1 | MESOGENIC STABILIZERS | BMI1, METTL14, PYM1 | ESR2 3153/4885PTGS2 4369/4885MAPT 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.